Recommended dose for repair of serum vitamin A levels in patients with HIV infection/AIDS may be insufficient because of high urinary losses.
OBJECTIVE
Retinol deficiency is quite frequent in the population of human immunodeficiency virus (HIV)-infected individuals. Serum retinol levels of less than 1.05 micromol/L determine a 3.5 to five times higher death risk. However, studies evaluating the efficacy of retinol supplementation in HIV-seropositive individuals have reported conflicting results. The World Health Organization recommends the treatment of vitamin A deficiency in seropositive individuals in the same manner as for seronegative individuals, but clinical studies proving the efficacy of this scheme are lacking. The proposal of the present study was to assess the efficacy of supplementation with high retinol doses in HIV-infected patients with vitamin A deficiency.


METHODS
Twenty-five adult HIV-seropositive individuals were monitored over a period of 9 months, with determination of serum and urinary retinol every 3 months. The subjects received retinol palmitate doses ranging from 300,000 IU to 600,000 IU. Patients whose retinol levels were higher than 1.60 micromol/L were only observed.


RESULTS
Eighteen patients received supplementation during clinical monitoring. The dose of 600,000 IU induced a significant mean increase in serum levels of 0.47 micromol/L (P = 0.049) within a period of three months. Those who received 300,000 IU presented a mean increase of 0.29 micromol/L. In contrast, the patients who did not receive replacement therapy presented a significant decrease (P = 0.017) in serum retinol levels, with initial and final values of 1.77 micromol/L and 1.55 micromol/L. The individuals with the worst response to supplementation presented a higher urinary loss of retinol at the beginning of the study. Even with a mean retinol supplementation of 771,428 IU during the study period, six patients had marginal serum retinol levels at the end of the study.


CONCLUSIONS
We conclude that, in view of the high urinary loss of this nutrient, there is the need to redefine the ideal dose for the treatment of HIV-infected individuals.
Neves
Fabio F
FF
Division of Infectious and Tropical Diseases, Department of Internal Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Ribeirão Preto, Brazil. fabioneves@hcrp.fmrp.usp.br
Vannucchi
Hélio
H
Jordão
Alceu A
AA
Figueiredo
José Fernando C
JF
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000150:complications / Q000378:metabolism; D000328:Adult; D018791:CD4 Lymphocyte Count; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009751:Nutritional Requirements; D018579:Patient Selection; D016896:Treatment Outcome; D019562:Viral Load; D014801:Vitamin A / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use* / Q000652:urine; D014802:Vitamin A Deficiency / Q000188:drug therapy* / Q000209:etiology; D014815:Vitamins / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use / Q000652:urine
D014815:Vitamins; D014801:Vitamin A